{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-25-000006","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.143329+00:00","generated_at":"2026-05-28T06:17:14.838507+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B","bullets":["Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.","FY2025 revenue guidance $2.66-2.69B; fully diluted non-GAAP EPS $3.40-$3.50.","CEO highlights record product launches and highest Enabling Technology placements post-NuVasive merger.","Full Q4 and FY2024 results to be reported on February 20, 2025 after market close."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-25-000006","json":"https://secwatch.observer/filing/0001562762-25-000006.json","markdown":"https://secwatch.observer/filing/0001562762-25-000006.md","text":"https://secwatch.observer/filing/0001562762-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276225000006/0001562762-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276225000006/gmed-20250108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:17:14.838507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}